Zoetis says the new product is designed to stimulate both cell-mediated and antibody-based immunity, providing a broad immune response that mimics a natural infection.
The company says CircoMax Myco has demonstrated robust performance in field conditions, delivering improvements in average daily gain (ADG) and close-out weights versus negative controls, helping producers get more kilograms of pork to market.
CircoMax Myco comes in a ready to use single-dose combination with a duration of immunity (DOI) of 23 weeks against both PCV2 and M. hyopneumoniae.
Alvaro Aldaz, Director, Global Commercial Development, Swine, Zoetis, said: “The swine industry needs to adapt to evolving challenges and our research has consistently demonstrated that with its unique technology CircoMax Myco offers robust protection against PCV2 and M. hyopneumoniae.
"It also shows that this new product offers the best chance at protection against continuously evolving PCV2 genotypes – providing a broader umbrella for pig health and productivity.
"Analysis of new European PCV2 strains isolated in multiple countries confirm that CircoMax Myco offers broader coverage than competitor vaccines based on PCV2a only.”
PS: Whilst you're here, take a moment to see our latest job opportunities for vets.